News and Announcements
Métier Medical Limited – CEO Interview
- Published March 25, 2014 9:44AM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Needlestick injury and reuse is an endemic problem throughout the developed and developing world and never has there been such an awareness of the financial and human cost as in recent times. The National Institute for Occupational Safety & Health estimates between 600,000 to 800,000 needlestick injuries every year in the USA alone and the figures in Australia are rising every year.
Please listen to Jan Wayland, Director.
Executive Interviews
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
Backed By Leading Investment Groups and Family Offices
